



Cite this article: Young BE, Mak TM, Ang LW,
Sadarangani S, Ho HJ, Wilder-Smith A,
Barkham T, Chen M (2020). Influenza vaccine
failure in the tropics: a retrospective cohort
study of waning effectiveness. Epidemiology
and Infection 148, e299, 1–8. https://doi.org/
10.1017/S0950268820002952
Received: 26 August 2020
Revised: 12 November 2020
Accepted: 26 November 2020
Key words:





© The Author(s), 2020. Published by
Cambridge University Press. This is an Open
Access article, distributed under the terms of
the Creative Commons Attribution licence
(http://creativecommons.org/licenses/by/4.0/),
which permits unrestricted re-use,
distribution, and reproduction in any medium,
provided the original work is properly cited.
Influenza vaccine failure in the tropics:
a retrospective cohort study of waning
effectiveness
B. E. Young1,2 , T. M. Mak3, L. W. Ang4, S. Sadarangani1,2, H. J. Ho5,
A. Wilder-Smith2,6,7, T. Barkham8,9 and M. Chen1,10
1National Centre for Infectious Diseases, Singapore; 2Lee Kong Chian School of Medicine, Nanyang Technological
University, Singapore; 3National Public Health Laboratory, National Centre for Infectious Diseases, Singapore;
4National Public Health and Epidemiology Unit, National Centre for Infectious Diseases, Singapore; 5Department
of Clinical Epidemiology, Office of Clinical Epidemiology, Analytics, and Knowledge, Singapore; 6London School of
Hygiene and Tropical Medicine, London, UK; 7Heidelberg Institute of Global Health, University of Heidelberg,
Germany; 8Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore; 9Department of Microbiology
and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore and 10Saw Swee
Hock School of Public Health, National University of Singapore, Singapore
Abstract
Influenza vaccine effectiveness (VE) wanes over the course of a temperate climate winter
season but little data are available from tropical countries with year-round influenza virus
activity. In Singapore, a retrospective cohort study of adults vaccinated from 2013 to 2017
was conducted. Influenza vaccine failure was defined as hospital admission with polymerase
chain reaction-confirmed influenza infection 2–49 weeks after vaccination. Relative VE was
calculated by splitting the follow-up period into 8-week episodes (Lexis expansion) and the
odds of influenza infection in the first 8-week period after vaccination (weeks 2–9) compared
with subsequent 8-week periods using multivariable logistic regression adjusting for patient
factors and influenza virus activity. Records of 19 298 influenza vaccinations were analysed
with 617 (3.2%) influenza infections. Relative VE was stable for the first 26 weeks post-vac-
cination, but then declined for all three influenza types/subtypes to 69% at weeks 42–49
(95% confidence interval (CI) 52–92%, P = 0.011). VE declined fastest in older adults, in indi-
viduals with chronic pulmonary disease and in those who had been previously vaccinated
within the last 2 years. Vaccine failure was significantly associated with a change in recom-
mended vaccine strains between vaccination and observation period (adjusted odds ratio
1.26, 95% CI 1.06–1.50, P = 0.010).
Introduction
Development of an influenza vaccine began soon after the virus was first isolated from humans
during the winter epidemic of 1932–1933 [1]. While vaccine design has evolved from whole-
virus to less reactogenic split-virion and subunit vaccines, they continue to rely on generating
antibodies against the highly variable haemagglutinin (HA) head for effectiveness [2].
The duration of protection after vaccination appears to be relatively short [3, 4]. This was
illustrated in a human challenge study with A/H1N1 conducted in 102 long-term adult male
residents of Yipsilanti State Hospital by Francis et al., in 1942 [5]. Fever >100°F (37.8 °C)
developed in half (18/36) of the unvaccinated controls, 32.1% (9/28) of the group vaccinated
4 1/2 months earlier, but only 15.8% (6/38) of individuals vaccinated 2 weeks previously.
Analysis of data collected from clinical trials and test-negative design (TND) case−control
studies have also indicated vaccine effectiveness (VE) wanes in the months after vaccination
[6–8]. The largest study to date, a TND study of 49 272 individuals in California estimated
the odds for influenza infection increased by 16% for each additional 28-days since vaccin-
ation, reaching an odds ratio (OR) of 2.06 (95% confidence interval (CI) 1.69–2.51) more
than 154 days after vaccination [9, 10].
TND studies have become the preferred observational study design for assessing influenza
VE. However, they typically enrol a large proportion of unvaccinated individuals and hence are
an indirect method of measuring changes in VE with time. TND studies have also mainly
enrolled outpatients with mild infections, have not been powered to identify patient risk fac-
tors for waning VE and are limited by inherent biases [11, 12].
The duration of protection following influenza vaccination is important for optimising the
timing of vaccine administration in temperate regions but is of particular interest in tropical
and sub-tropical climates where influenza activity is not confined to a relatively short winter
season [13]. In these regions, multiple annual outbreaks and continuous year-round transmis-
sion are frequently observed [14]. The timing of outbreaks can also be highly variable, which
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complicates determining the best time of year to vaccinate [15].
Limited data are available from tropical countries, but TND stud-
ies from Thailand, Kenya and Singapore indicate VE continues to
decline throughout the year after vaccination [16–18].
We conducted a cohort study of influenza vaccine recipients
and measured changes in the risk of severe influenza infection
with time post-vaccination in a tropical setting with year-round
influenza virus activity.
Methods
We conducted a retrospective cohort study in Singapore.
All influenza vaccinations administered to Singapore residents
aged ⩾21 years at National Healthcare Group (NHG) facilities
between 1 January 2013 and 22 July 2017 were identified from
a regional vaccination database. The NHG cluster operates public
healthcare facilities in Singapore, including Tan Tock Seng
Hospital (TTSH) a 1500 bedded tertiary hospital and six polycli-
nics (government-funded primary care clinics) which serve 834
000 patients annually [19].
Vaccination records were matched with electronic medical
records of each individual’s demographics, co-morbidities and
hospitalisations at TTSH. Vaccination records were also matched
with TTSH laboratory records of influenza polymerase chain
reaction (PCR) tests conducted between 1 January 2013 and 30
September 2017. All influenza PCRs were conducted as part of
routine clinical care and used the abTES Flu qPCR Kit
(AitBiotech, Singapore). This is a 4-plex real-time assay that
tests for influenza A with H3N2 and H1N1-specific subtyping
and influenza B. Lineage (B/Victoria; B/Yamagata) is not available
with this assay.
Influenza vaccine failure was defined as a positive influenza
PCR within 2–49 weeks (14–349 days inclusive) after vaccination
and associated with admission to TTSH. Vaccine failure was
tagged to the most recent influenza vaccine received prior to
infection.
Time following vaccination was split in a Lexis expansion into
six sequential 8-week observation periods per subject. The first
observation period, weeks 2–9 after vaccination (days 14–69),
was the reference to which subsequent observation periods were
compared. These periods covered weeks 10–17, 18–25, 26–33,
34–41 and 42–49 post-vaccination. Each vaccination was followed
for 49 weeks until death, PCR-confirmed influenza, another vac-
cination (at which time a new observation is started) or the study
end date (30 September 2017).
Because of the changing pattern of influenza virus activity over
the course of the study, seasonal influenza activity was estimated
for each study participant for each 8-week observation period.
Virus activity was estimated from the number of positive influ-
enza PCRs recorded at TTSH for that observation period as a pro-
portion of infections for the total duration of the study.
Predictors of influenza vaccine failure were identified by multi-
variable logistic regression of the whole cohort. Subsequently, the
odds of influenza infection in each observation period compared
with the first period and adjusted for predictors of vaccine failure
was calculated (adjusted odds ratio (aOR)). VE relative to the first
period was calculated by (1/aOR) × 100. We conducted sub-group
analysis to explore the relative impact of the main predictors of
influenza vaccine failure on changes in VE with time since vaccin-
ation. Observation periods were additionally modelled as a con-
tinuous variable to estimate the overall trend.
Influenza infections during periods where a recommended
vaccine strain had not changed for more than 1 year and
where the infected individual had received that vaccine were iden-
tified and the sample was retrieved for sequencing. RNA was
extracted and whole genome amplification was achieved by
reverse transcription PCR (RT-PCR) using Superscript® III
One-Step RT-PCR System with Platinum® Taq DNA polymerase
(Invitrogen) [20]. RT-PCR products were pooled, libraries were
Fig. 1. Flow diagram of study.
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prepared using the Nextera XT DNA lkit and sequenced on the
MiSeq instrument (Illumina). HA sequences were processed
and assembled using a customised pipeline of open-source
software programs (unpublished). Phylogenetic analysis was
performed using MEGA 6 (https://www.megasoftware.net) using
maximum likelihood test with 1000 bootstrap replicates. Key
amino acid changes were identified using FluServer [21].
Statistical analysis was performed using R version 3.6.1
(R Foundation for Statistical Computing, Vienna, Austria).
Statistical significance was assumed with P < 0.05. For the initial
multivariable logistic regression model of influenza vaccine failure,
the Bonferroni correction was applied to account for multiple com-
parisons when selecting variables to include in the logistic regression
model. Variables were removed by backwards elimination. Statistical
tests included Student’s t test for continuous variables and chi-square
test for categorical variables. This study was approved by the institu-
tional ethics committee (Ref: 2017/00691) with a waiver of informed
consent from participants. Data analysed in this paper are available
from the corresponding author on reasonable request.
Results
Influenza vaccinations
A total of 19 298 vaccinations met study inclusion criteria
and were administered to 11 462 Singapore residents (Fig. 1).
All were standard-dose (15 mcg HA per strain) egg-cultured inac-
tivated influenza vaccine without adjuvant. Strain composition
reflected contemporary World Health Organization (WHO)
recommendations and changed every 6 months to the Northern
Hemisphere or Southern Hemisphere vaccine (Supplementary
Table 1). Vaccines were either subunit or split-virion and from
a range of manufacturers over the course of study. The majority
of vaccines administered were trivalent (95.8%). This was replaced
by the quadrivalent vaccine with two B strains in April 2017.
Vaccines were administered throughout the year (Fig. 2A).
The weekly number of vaccines administered increased from an
average of 57 per week in 2013 to 99 in 2017 (t test, P < 0.0001,
Supplementary Fig. 1). The majority of vaccines were adminis-
tered at the hospital, either during an inpatient admission
(42.6%) or at a specialist outpatient clinic (45.5%), while 11.8%
were administered at NHG polyclinics.
Influenza PCR
Of the 52 375 unique influenza PCR records over the study per-
iod, 6375 were positive and met study inclusion criteria.
Infections were detected year-round, but with biannual epidemics
(Fig. 2B). There was little variation in the number of negative
influenza tests between influenza epidemic and inter-epidemic
periods, however, there was a significant increase in the number
of tests per week over the course of the study (t test, P < 0.0001,
Supplementary Fig. 2). The majority of influenza infections
were type A (77.0%), with subtype AH3 comprising 82.0% and
AH1 18.0% (Fig. 2C). No avian influenza infections (e.g. AH5,
AH7) were detected in Singapore over the course of the study
(Supplementary Fig. 3).
Vaccine failure
In total, 652 influenza infection were identified within 14–365
days after administration of the 19 298 vaccines. After excluding
11 infections which were not associated with hospital admission
and 24 which occurred from week 50 to 52, 617 infections occurred
during the weeks 2–49 after vaccination, a vaccine failure rate of 3.2%.
Subject attrition due to death or end of follow-up was stable
across the six observation periods after influenza vaccination,
while re-vaccination rates steadily increased (Table 1).
Participants remaining in the study at later observation periods
were of a similar age to the baseline period, but had fewer
co-morbidities and were less likely to have been admitted in the
year prior to vaccination. Increasing age, higher Charlson’s
co-morbidity score, presence of chronic pulmonary disease, history
of hospital admission in the preceding year and receipt of influenza
vaccination received less than 2 years previously were significantly
associated with vaccine failure (Supplementary Table 2).
VE with time since vaccination
Despite a high infection rate in the 2–9 weeks after vaccination,
the aOR for any influenza infection relative to this period was
Fig. 2. (A) Number of influenza vaccines administered by month and vaccination
location (all years combined); (B) weekly number of unique influenza PCRs con-
ducted at Tan Tock Seng Hospital over the course of the study with a positive or
negative result; (C) weekly influenza subtype/type results reported from positive
influenza PCRs. AHx, Influenza A, subtype undetermined.
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significantly higher for the last two observation periods, weeks
34–41 and 42–49 (Fig. 3). There was a significant linear trend
of increased odds of influenza infection per period (aOR 1.07,
95% confidence interval (CI) 1.02–1.12). The trend was similar
when analysed by influenza type/subtype.
In the sub-groups at highest risk for influenza there was a sig-
nificantly increased odds of influenza infection with time since
vaccination (Fig. 4). These risk factors also had additive effects,
such that with an increasing number of risk factors (age ⩾65
years, chronic pulmonary disease, vaccination in previous 2
years), the incidence of hospitalisation with influenza also
increased with time and also the rate of waning VE
(Supplementary Fig. 4). The number of influenza vaccines
received in the previous 2 years was significantly associated with
both an increasing risk of influenza infection and waning VE
(Supplementary Fig. 5).
Table 1. Summary data by individual observation periods post-vaccination
Period 1 2 3 4 5 6
Weeks post-vaccination 2–9 10–17 18–25 26–33 34–41 42–49
Number of observation periods 19 298 17 747 16 451 15 275 14 070 12 762
Year of vaccination, n (%)
2013 3027 (15.7) 2975 (16.8) 2907 (17.7) 2852 (18.7) 2852 (20.3) 2852 (22.3)
2014 3300 (17.1) 3224 (18.2) 3157 (19.2) 3027 (19.8) 3027 (21.5) 3027 (23.7)
2015 5154 (26.7) 5006 (28.2) 4844 (29.4) 4660 (30.5) 4660 (33.1) 4660 (36.5)
2016 4802 (24.9) 4661 (26.3) 4527 (27.5) 4396 (28.8) 4396 (31.2) 4396 (34.4)
2017 3015 (15.6) 1881 (10.6) 1016 (6.2) 340 (2.2) 340 (2.4) 340 (2.7)
Change in vaccine straina, n (%)
Any 579 (3.0%) 3126 (17.6) 5492 (33.4) 7789 (51.0) 9064 (64.4) 10 375 (81.3)
AH3 255 (1.3%) 1776 (10.0) 3355 (20.4) 5281 (34.6) 6526 (46.4) 7952 (62.3)
AH1 167 (0.9%) 846 (4.8) 1238 (7.5) 1228 (8.0) 1276 (9.1) 1229 (9.6)
B 326 (1.7%) 1746 (9.8) 3306 (20.1) 5020 (32.9) 6285 (44.7) 7695 (60.3)
Attrition
Re-vaccination, n (%) 76 (0.39%) 97 (0.55%) 172 (1.0%) 326 (2.1%) 389 (2.8%) 1242 (9.7%)
All-cause mortality, n (%) 347 (1.8%) 298 (1.7%) 279 (1.7%) 251 (1.6%) 216 (1.5%) 176 (1.4%)
End of follow-up, n (%) - 1023 (5.3%) 787 (4.4%) 633 (3.8%) 522 (3.4%) 592 (4.2%)
Influenza infection
Number of infections, n (%) 105 (0.544) 114 (0.642) 92 (0.559) 106 (0.694) 111 (0.789) 89 (0.697)
Mean risk of infection compared with all time periodsb
All 0.983 0.908 0.963 1.065 1.083 1.031
AH3 1.024 0.895 0.949 1.044 1.063 1.052
AH1 0.917 0.928 0.994 1.103 1.102 0.997
B 0.907 0.929 0.980 1.100 1.125 1.006
Patient characteristics
Age, years, mean (S.D.)c 71.9 (14.7) 71.8 (14.7) 71.8 (14.7) 71.7 (14.7) 71.7 (14.6) 71.7 (14.7)
>85 years 19.6% 19.3% 19.1% 18.9% 18.8% 18.7%
>65 years 71.3% 71.3% 71.2% 71.1% 71.3% 71.0%
Male 56.7% 56.7% 56.8% 56.8% 56.5% 56.7%
Charlson comorbidity index,
mean (S.D.)
2.93 (2.53) 2.90 (2.52) 2.86 (2.50) 2.82 (2.48) 2.79 (2.47) 2.76 (2.46)
Chronic pulmonary disease 44.6% 44.6% 44.1% 43.9% 43.6% 42.9%
Hospitalisation in year prior to
vaccination
66.3% 65.7% 64.9% 64.5% 64.5% 64.0%
Vaccination in the 2 years prior to
index vaccine
45.5% 45.1% 44.8% 44.7% 44.1% 43.5%
aChange in vaccine strain is defined as the availability of vaccine with a new strain composition between the date of vaccination and date of onset of the observation period.
bEstimated average risk of influenza for that observation period compared with all 95 603 time periods under observation. Numbers >1 indicate greater than average risk.
cMean age and age categories adjusted from date of vaccination to onset of the observation period. S.D., standard deviation.
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Effect of changing vaccine strain recommendations
The recommended strain composition of the trivalent vaccine
changed five times over the course of the study, with changes to
seven vaccine strains: three times for influenza AH3 (new strains
Southern Hemisphere (SH) 2014, SH 2015, SH 2016), three times
for B (new strains Northern Hemisphere (NH) 2013/14, SH 2015,
SH 2016) and once for AH1 (SH 2017).
The proportion of observation periods which occurred after
the vaccine strain had changed but the individual had not been
re-vaccinated, increased with time since vaccination (Table 1).
Overall, 26.3% of AH3, 6.3% of AH1 and 25.5% of B observation
periods followed a change in the vaccine strain between SH and
NH vaccine or vice versa. The observation periods following a
change in vaccine strain were strongly associated with higher
AH3 and AH1 influenza virus activity (both P < 0.0001), but sig-
nificantly lower influenza B activity (P < 0.0001). After adjusting
for other predictors of influenza vaccine failure, including virus
activity, change in vaccine strains was associated with an
increased odds of influenza infection (aOR 1.26, 95% CI 1.06–
1.50, P = 0.010). Of note, for the subgroup of individuals for
which there was no change in vaccine strain recommendations
between reference and observation period, VE still waned with
time since vaccination (aOR, 1.09, 95% CI 1.01–1.171, P = 0.030).
Effect of antigenic drift on VE
Vaccine strain recommendations were stable for longer than 1
year for AH1 infections from January 2013 to April 2017 and
for AH3 from May 2016 to October 2017. A total of 62 AH3 clin-
ical samples from individuals receiving the A/Hong Kong/4801/
2014 vaccine strain were sequenced. All 62 sequences belonged
to the 3C.2a clade and contained the K160T mutation, which
resulted in the potential gain of a glycosylation site within anti-
genic site B (Supplementary Fig. 6). No increase in mutations
was observed with increasing time from vaccination (Table 2).
A/H1N1 HA sequences were successfully retrieved from 14 vacci-
nated individuals. All sequences belonged to clade 6B, with only
one clinical specimen bearing the G155E mutation that was asso-
ciated with reduced recognition by antisera against A/California/
7/2009 (Supplementary Fig. 7).
Discussion
In a tropical country where the influenza virus circulates year-
round, the effectiveness of the standard-dose vaccine at preventing
hospital admission with influenza infection declined significantly
in the months following vaccination. This decline was most evident
in individuals at the highest risk for complications associated with
influenza, including older adults and those with chronic pulmonary
disease. It is of concern that having received more than one vaccine
in a 2-year period was associated with reduced VE and faster waning
of protection. The results of this study offer insights into the optimal
timing of influenza vaccination in temperate climates and for the
40% of the global population residing in the tropics.
Change in influenza VE after vaccination is the consequence of
two main factors: firstly, the initial immune response to vaccin-
ation and subsequent waning of vaccine-induced protective
immunity and secondly, antigenic drift that diminishes the
match between the vaccine and circulating strains [22].
The most readily observable antigenic drift occurs when
vaccine strains are updated between the NH and SH winters
Fig. 3. Adjusted influenza vaccine effectiveness (aVE) for influenza infection overall and by influenza type/subtype for each time period relative to the first period
(weeks 2–9 after vaccination). The estimates were adjusted for age, sex, ethnicity, chronic pulmonary disease, hospital admission in the previous year, previous
influenza vaccination in the 2 years before the index date of vaccination and influenza virus activity during that time period. The error bars indicate 95% confidence
interval (CI). aOR, adjusted odds ratio.
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(and vice versa). As a consequence of biannual changes to vaccine
strain composition, an individual may be inadequately protected
against circulating strains despite receiving annual vaccination.
The data from our study indicate that change in vaccine strains
is a risk factor for vaccine failure regardless of how recently the
prior vaccine was administrated. While such a result is not sur-
prising, to our knowledge evidence in this context has not previ-
ously been presented and suggests that in tropical countries when
there is a change in recommended vaccine strain, individuals at
highest risk of complications should be re-vaccinated regardless
of when they received the previous vaccine [23].
Antigenic drift is also expected to result in increasing antigenic
mismatch between vaccine and circulating virus before vaccine
strains are updated. For example, an analysis of AH3 sequences
from clinical samples in Thailand described increasing divergence
of circulating strains from the 2016 vaccine strain with time [24].
Predicted VE declined from 74% in 2016 to 48% in 2017.
Although limited by the number of AH3 samples sequenced,
we did not find a significant association between antigenic drift
and time since vaccination after matching by the week of infec-
tion. However, a comprehensive assessment would require under-
standing what was circulating in the community at the same time.
Antigen mismatch is not, however, an all or none phenom-
enon. Antigenic cartography maps how antibody to the HA or
neuraminidase of one influenza strain binds to drifted strains
with lower affinity, indicating higher titres would be required
for protection against infection [25, 26]. Haemagglutination
inhibition (HI) titres clearly wane with time following influenza
vaccination or infection and are unlikely to persist year-round
in older adults [27]. In individuals with diminished immune
responses to vaccination – likely to include older adults and
those who have received repeated influenza vaccination – waning
of protective antibody will thus affect the duration of VE against
matched and mismatched circulating virus.
The effects of mismatch and waning immunity have two
potential solutions. A number of influenza vaccines which offer
enhanced immunogenicity to the standard-dose are available:
the recombinant influenza vaccine (RIV), high-dose vaccine
Fig. 4. Adjusted vaccine effectiveness against influenza infection by subgroup for
each time period relative to the first period (weeks 2–9 after vaccination), with a
linear trend line. Estimates were adjusted for age, sex, ethnicity, chronic pulmonary
disease, hospital admission in the previous year and previous influenza vaccination in
2 years before the index date of vaccination. The error bars indicate 95% confidence
interval (CI). A significant trend of a declining VE with time since vaccination was only
observed in those sub-groups at higher risk for influenza vaccine failure (<65 years
P = 0.104, ⩾65 years P = 0.0216; no chronic pulmonary disease P = 0.609, chronic pul-
monary disease P = 0.00012; No vaccination for >2 years P = 0.901, previous vaccin-
ation P < 0.0001).
Table 2. Number of mutations compared to influenza vaccine strain










7 2 1 3
9 1 1 2
10 1 0 1
11 3 3 6
12 7 1 8
13 10 12 22
14 7 7 14
15 1 4 5
17 0 1 1




32 of the HA sequences were from patients with infection within 181 days post-vaccination
and 30 of the HA sequences were from patients with infection within 182–349 days
post-vaccination. Number of mutations was not significantly different between the two time
periods (t test, mean difference −0.79 (95% CI −1.75 to 0.18) P = 0.107). HA, haemagglutinin.
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(IIV-HD) and vaccines containing the MF-59 adjuvant (aIIV).
Clinical trials conducted in temperate climates have also
demonstrated that RIV and IIV-HD offer superior vaccine
efficacy compared to the standard dose vaccine [28, 29].
Evidence that these vaccines will extend the duration of clinical
protection to year-round is not currently available. Although
these vaccines clearly offer superior HI titres at seroconversion,
there is little data currently available of HI titres 180 or 360
days after vaccination [30]. It may be that these vaccines offer a
short-term boost to titres, which then decay more rapidly.
Again, these issues are likely to be most significant in vulnerable
groups such as older adults and those with co-morbidities.
An alternative to these ‘enhanced’ vaccines is to administer the
standard dose twice a year. Biannual vaccination with the same
vaccine strains has been shown to boost HI titres against AH3
and AH1 in a clinical trial conducted in older adults in
Singapore [31]. Whether the higher HI titre is substantial enough
to reduce influenza infections and whether this approach is cost-
effective, needs to be demonstrated.
Another question is whether VE wanes at different rates with
different influenza subtypes or strains [32]. The immune conse-
quences of influenza infection during early childhood persist life-
long and may result in a birth cohort effect on the duration of VE
[33]. This study was unable to address this adequately due to the
relatively small number of infections. VE appeared to wane faster
with AH1 compared to AH3, which is consistent with lower AH1
HI titres at seroconversion and after 6 months reported from the
study of biannual vaccination [31]. However, this finding may also
reflect the lower absolute effectiveness of the vaccine against AH3
infection compared to AH1. It is difficult to detect waning effect-
iveness if the vaccine is suboptimally effective to start with.
This study has a number of limitations. It is a retrospective,
observational study with vaccines administered – and infections
detected – year-round. While there is the possibility of incorrectly
coded administrative data a previous study conducted in 2016 at
TTSH indicated there was no significant difference in the
extracted Charlson’s comorbidity score compared with manual
chart review [34]. Some data, such as body habitus or smoking
history was not available, but may be important predictors of
VE. The virus activity score accurately predicted the observed
number of influenza infections in the cohort (data not shown)
but other factors will determine an individual’s risk of being
exposed to influenza which we were unable to measure.
Although we had access to records at NHG, we were not able
to capture vaccinations and hospital admissions at other health-
care groups. As the probability of re-vaccination increased with
time since index vaccine was received, this omission would be
expected to bias against the detection of waning VE. Singapore
has historically had a low uptake of the influenza vaccine esti-
mated at 15.2% for adults aged ⩾50 years from a national survey
conducted in 2013 [35].
This study examined a cohort that included a large proportion
of older adults and those with comorbidities where the burden of
influenza is greatest. We only studied severe influenza – i.e. infec-
tions associated with hospital admission – but as a result we are
not able to distinguish whether the observed waning reflects a
change in infection rates with time or a change in the severity
of infection [36]. Influenza vaccination has been reported to
reduce the severity of breakthrough infection in hospitalised indi-
viduals and presumably this protection would also wane with time
[37]. This effect may explain why waning VE was more evident in
patients with chronic pulmonary disease. Reduced VE with
repeated years vaccination may also reflect individuals with a
higher burden from co-morbidities – and hence more frequent
hospital attendances and opportunities for vaccination. This pos-
sibly resulted in confounding due to an unhealthy vaccinee bias to
which we had insufficient data to adjust for.
In conclusion, the implications of year-round influenza circu-
lation on vaccination strategies are beginning to be explored. This
study provides important data to support the hypothesis that
annual standard-dose vaccination is unlikely to provide optimal
protection. Exploration of alternative strategies in adults at high
risk for severe influenza should be a public health priority.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0950268820002952.
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